Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007–2014

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Infectious Diseases

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/cid/ciw632PMID 27624959
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.

  2015influential reference
• Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.

  2014cited by this paper
• Molecular Epidemiology of the Pertussis Epidemic in Washington State in 2012

  2014cited by this paper
• Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

  2014cited by this paper
• Pertussis pathogenesis--what we know and what we don't know.

  2014cited by this paper
• Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

  2014cited by this paper
• Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia

  2014influential reference
• Antibody-mediated inhibition of Bordetella pertussis adenylate cyclase-haemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population.

  2014influential reference
• Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.

  2014cited by this paper
• Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.

  2014cited by this paper
• Changing pertussis epidemiology: everything old is new again.

  2014influential reference
• Virulence of Pertactin-Negative Bordetella pertussis Isolates from Infants, France

  2013cited by this paper
• Waning Immunity to Pertussis Following 5 Doses of DTaP

  2013cited by this paper
• Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

  2013cited by this paper
• Prevalence and Molecular Characterization of Pertactin-Deficient Bordetella pertussis in the United States

  2013cited by this paper
• Pertactin-negative variants of Bordetella pertussis in the United States.

  2013influential reference
• Pertussis resurgence: waning immunity and pathogen adaptation – two sides of the same coin

  2013cited by this paper
• Waning protection after fifth dose of acellular pertussis vaccine in children.

  2012cited by this paper
• Pertussis control: time for something new?

  2012cited by this paper
• Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

  2012cited by this paper
• Number and order of whole cell pertussis vaccines in infancy and disease protection.

  2012cited by this paper
• Population Diversity among Bordetella pertussis Isolates, United States, 1935–2009

  2012cited by this paper
• Pertussis epidemic--Washington, 2012.

  2012cited by this paper
• Prevalence and Genetic Characterization of Pertactin-Deficient Bordetella pertussis in Japan

  2012cited by this paper
• Appearance of Bordetella pertussis Strains Not Expressing the Vaccine Antigen Pertactin in Finland

  2012cited by this paper
• Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.

  2010cited by this paper
• Pertactin Is Required for Bordetella Species To Resist Neutrophil-Mediated Clearance

  2010cited by this paper
• First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.

  2009cited by this paper
• Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?

  2003cited by this paper
• Crucial role of antibodies to pertactin in Bordetella pertussis immunity.

  2003cited by this paper
• Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life.

  2003cited by this paper
• Immunity to Bordetella pertussis.

  2001cited by this paper
• Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

  2001cited by this paper
• Epidemiological Typing of Bordetella pertussis Isolates: Recommendations for a Standard Methodology

  2000cited by this paper
• Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization

  1999cited by this paper
• A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine

  1998cited by this paper
• Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.

  1997cited by this paper
• A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

  1996cited by this paper

• Pertussis resurgence: epidemiological trends, pathogenic mechanisms, and preventive strategies

  2025cites this paper
• Pertactin deficiency of Bordetella pertussis: Insights into epidemiology, and perspectives on surveillance and public health impact

  2024cites this paper
• Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants: a multicenter study in France, 2008-2019.

  2024cites this paper
• Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations

  2023cites this paper
• Risk factors and prediction model of severe pertussis in infants < 12 months of age in Tianjin, China

  2022cites this paper
• Non-primate animal models for pertussis: back to the drawing board?

  2022cites this paper
• Can vaccines control bacterial virulence and pathogenicity? Bordetella pertussis: the advantage of fitness over virulence

  2022cites this paper
• Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.

  2021cites this paper
• Naturally circulating pertactin-deficient Bordetella pertussis strains induce distinct gene expression and inflammatory signatures in human dendritic cells

  2021cites this paper
• Pertussis

  2020cites this paper
• Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines

  2018influential citation
• Will we have new pertussis vaccines?

  2017cites this paper
• Severe pertussis infection in infants less than 6 months of age: Clinical manifestations and molecular characterization

  2017cites this paper
• Genotypic characterization by multi locus variable number of tandem repeats analysis international Bordetella pertussis vaccine strains

  2017cites this paper